Improved hepatitis A and hepatitis B vaccination strategy is necessary for patients with chronic hepatitis C

Maqsood, Muhammad Haisum; Kolli, Himabindu; Kaur, Satinder; Reyes, Karen J. Campoverde; Guevara, Javier Nieto; Shah, Pir Ahmad; Talat, Arslan; Lau, Daryl

doi:10.1093/gastro/goaa024

Cited by 3 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Amidst these challenges, vaccine hesitancy remains a formidable barrier to achieving comprehensive immunization coverage within this patient group. Factors contributing to this hesitancy include socioeconomic disparities, fears regarding adverse effects, and skepticism about vaccine efficacy, necessitating targeted communication strategies and evidence-based interventions to mitigate these concerns [ 6 ]. Despite the general advocacy for vaccinations against influenza, pneumococcal disease, and viral hepatitis among CLD patients, there is a notable deficiency in systematic evaluations of vaccine efficacy specifically within this demographic with much of the supporting evidence extrapolated from studies on other immunocompromised populations [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Advancements in Vaccine Strategies for Chronic Liver Disease Patients: Navigating Post-COVID Challenges and Opportunities

Al-Dury,

Kanberg

2024

Vaccines

View full text Add to dashboard Cite

This review addresses the vital role of vaccinations in managing patients with chronic liver disease (CLD), especially in the context of the post-COVID-19 landscape. The pandemic has highlighted the unique vulnerabilities of CLD patients, including those awaiting liver transplantation and post-transplant individuals, who face heightened risks of infection due to compromised immune responses. Recent advancements in vaccine technology, such as mRNA platforms, novel adjuvants, and advanced delivery systems, have significantly accelerated vaccine development, enhancing both speed and efficacy. Moreover, the emergence of personalized vaccines, tailored to everyone’s unique immunological profile, presents new opportunities, particularly for those with chronic conditions. This review synthesizes the current state of evidence regarding vaccine recommendations for CLD patients, focusing on their response to vaccinations and proposing effective strategies to protect this vulnerable group from vaccine-preventable diseases. It also explores the challenges in implementing these strategies and considers the impact of emerging vaccine delivery systems on improving outcomes for CLD patients. The paper aims to provide nuanced guidance on vaccination in the rapidly evolving healthcare landscape, addressing both technological innovations and comprehensive patient care strategies.

show abstract

Section: Introductionmentioning

confidence: 99%

Advancements in Vaccine Strategies for Chronic Liver Disease Patients: Navigating Post-COVID Challenges and Opportunities

Al-Dury,

Kanberg

2024

Vaccines

View full text Add to dashboard Cite

show abstract

“…No estudo de Maqsood et al 85 A obesidade é o maior fator de risco para o desenvolvimento de diabetes mellitus tipo 2; 53% dos adultos com diabetes são obesos 98 .…”

Section: Raçaunclassified

Avaliação da imunogenicidade anti-HBV em portadores crônicos do vírus da hepatite C não cirróticos após exposição a dois esquemas de vacina contra hepatite B

Medeiros¹

View full text Add to dashboard Cite

Impaired anti-HBV vaccine response in non-cirrhotic chronic HCV is not overcome by double dose regimen: randomized control trial

Medeiros

Terrault

Mazo

et al. 2023

Annals of Hepatology

View full text Add to dashboard Cite

Improved hepatitis A and hepatitis B vaccination strategy is necessary for patients with chronic hepatitis C

Cited by 3 publications

References 8 publications

Advancements in Vaccine Strategies for Chronic Liver Disease Patients: Navigating Post-COVID Challenges and Opportunities

Advancements in Vaccine Strategies for Chronic Liver Disease Patients: Navigating Post-COVID Challenges and Opportunities

Avaliação da imunogenicidade anti-HBV em portadores crônicos do vírus da hepatite C não cirróticos após exposição a dois esquemas de vacina contra hepatite B

Impaired anti-HBV vaccine response in non-cirrhotic chronic HCV is not overcome by double dose regimen: randomized control trial

Contact Info

Product

Resources

About